---
title: "SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285859735.md"
description: "SSY Group has received regulatory approval in China for Oseltamivir Phosphate capsules, enhancing its antiviral portfolio. The company also secured approvals for Drotaverine Hydrochloride and Metoclopramide tablets, expanding its offerings in gastrointestinal and antispasmodic therapies. These developments position SSY Group to benefit from the demand for flu treatments and strengthen its competitive standing in the generic pharmaceutical market. The latest analyst rating for SSY Group (HK:2005) is a Buy with a price target of HK$5.00."
datetime: "2026-05-11T00:37:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285859735.md)
  - [en](https://longbridge.com/en/news/285859735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285859735.md)
---

# SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

SSY Group ( (HK:2005) ) has provided an update.

SSY Group has received Chinese regulatory approval to produce and market Oseltamivir Phosphate capsules in multiple strengths, a key antiviral used to treat and prevent influenza A and B across various age groups. The approval, with consistency evaluation status, enhances the company’s antiviral portfolio and positions it to benefit from ongoing demand for flu treatments in China.

The company has also secured approvals, as one of the earliest domestic producers, for Drotaverine Hydrochloride tablets and Metoclopramide tablets, both classified as type 3 drugs and deemed to have passed consistency evaluation. These new gastrointestinal and antispasmodic therapies, supported by previously approved bulk drug registrations, broaden SSY Group’s oral solid dosage offerings and may strengthen its competitive standing in China’s generic pharmaceutical market.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

**More about SSY Group**

SSY Group Limited is a China-focused pharmaceutical manufacturer specializing in chemical drugs and injectable preparations for hospital and clinical use. The group develops and produces a range of therapeutic products targeting infectious diseases, gastrointestinal conditions and pain-related disorders for both adult and paediatric patients in the domestic market.

**YTD Price Performance:** -15.19%

**Average Trading Volume:** 9,805,927

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$7.08B

Learn more about 2005 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)

## Related News & Research

- [SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025](https://longbridge.com/en/news/280725971.md)
- [SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio](https://longbridge.com/en/news/285308388.md)
- [Roche, Medicines Patent Pool sign deal to expand access to influenza drug](https://longbridge.com/en/news/286796802.md)
- [Metals Creek Resources Corp. File for Final Approval of Private Placement | MCREF Stock News](https://longbridge.com/en/news/286966727.md)
- [AIA Singapore targets 90% of illness claims](https://longbridge.com/en/news/287132135.md)